Evaluation of Pneumococcal Vaccine Formulations in Young Adults

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in young adults. Subjects will be vaccinated twice with an interval of two months.

Clinical Trial Description

This amendment was due to

- The addition of secondary endpoints for safety. The collection of data related to these secondary safety endpoints was already planned and the corresponding statistical analyses were described in the statistical section.

- The addition of an exclusion criterion regarding the administration of immunoglobulins and blood products. It is already included in the elimination criteria section. It impacts only immunogenicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00707798
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	June 30, 2008
Completion date	January 15, 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01641133` - Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™	Phase 3
Completed	`NCT01204658` - Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants	Phase 2
Completed	`NCT00370396` - Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.	Phase 3
Completed	`NCT02838407` - Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.	N/A
Completed	`NCT00523770` - Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoniae	N/A
Completed	`NCT00756067` - Evaluation of Pneumococcal Vaccine Formulations in Elderly	Phase 1
Completed	`NCT00345358` - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT01153893` - Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria	Phase 3
Completed	`NCT00307541` - Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT00547248` - Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines	Phase 3
Withdrawn	`NCT01160055` - Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children	N/A
Completed	`NCT00370227` - Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT00390910` - Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants	Phase 3
Completed	`NCT00985751` - Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination	Phase 2
Withdrawn	`NCT01031329` - Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey	N/A
Completed	`NCT00307554` - A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study	Phase 3
Completed	`NCT02270944` - Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine	Phase 2
Completed	`NCT01235949` - Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment	Phase 4
Completed	`NCT00985465` - Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali	Phase 3
Completed	`NCT00861380` - Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease	Phase 3